COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Umbilical Cord Blood in the Treatment of Stroke in Children. (Pedi Stroke)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01700166
Recruitment Status : Withdrawn (Principal Investigator relocated; Study may resume in Fl Hosp. for Children, Orlando FL)
First Posted : October 4, 2012
Last Update Posted : January 23, 2014
The Institute for Rehabilitaion and Research Foundation
Cord Blood Registry, Inc.
The University of Texas Health Science Center, Houston
M.D. Anderson Cancer Center - Houston
Baylor College of Medicine
Information provided by (Responsible Party):
James E.Baumgartner, MD, Memorial Hermann Health System

Brief Summary:

The specific aims of this study are:

  1. To determine if Human Umbilical Cord Blood (hUCB) infusion is safe in children with perinatal arterial ischemic stroke (AIS).
  2. To determine if late functional outcome, physiologic response, and anatomic findings are changed following hUCB infusion in children with perinatal AIS.

Condition or disease Intervention/treatment Phase
Arterial Ischemic Stroke (AIS) in Children Biological: Autologous Human Cord Blood derived Stem Cell injection Phase 1

Detailed Description:

This study will enroll ten pediatric patients who have their umbilical cord blood banked with Cord Blood Registry, Inc. (CBR), who have been diagnosed with an arterial ischemic stroke (AIS), and whose caregivers contacted CBR, Inc. to notify them that the child has experienced an AIS around the time of birth.

After receiving permission to release the patient's contact information, the CBR team will then relay the contact information to the Stem Cell Study Group at the University of Texas - Houston (UT) / Children's Memorial Hermann Hospital (CMHH) who will contact the family, explain the study, and send a consent form for their review.

Several weeks prior to the scheduled procedure date, the patient will go to their family doctor for a physical evaluation and have blood drawn to rule out problems with the child's health.

After successfully meeting initial pre-screening criteria, the patient's family will make their own arrangements to travel to Houston for the study procedures.

Once the patient is in Houston, he/she will undergo baseline assessments, including physical, neurological exams and tests, speech therapy testing, laboratory tests, and imaging (MRI) of the brain. If any of the blood tests are abnormal, or the patient has an active infection, the procedure may be postponed or the patient may possibly be excluded from the study.

If the patient continues to meet all criteria, the frozen cord blood will be shipped overnight to a special lab in Houston, TX for processing. Once release criteria have been met, the cells will be brought to the CMHH for infusion into the patient's vein. The patient will remain at CHMM for 24 hours of monitoring, after which they will be allowed to go home. Patients will be called daily by the research staff through Day 14, and once a month after that.

Patients will return to Houston, Texas for 6 month, 1 year and 2 year follow-up visits for repeat assessments, tests, and exams just like at the baseline visit. The MRI of the brain will only be repeated at the 6 month visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children.
Study Start Date : September 2012
Actual Primary Completion Date : August 2013
Estimated Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Biologic; Cord Blood Stem Cells; Intravenous injection
Autologous Human Umbilical Cord Blood derived Stem Cell injection
Biological: Autologous Human Cord Blood derived Stem Cell injection
One time intravenous (in the vein) injection with two year follow-up
Other Names:
  • Patient's own cord blood
  • Patient's own stem cells

Primary Outcome Measures :
  1. Functional outcome measure [ Time Frame: Two years ]
    Physiological (e.g., SSEP, EEG) and anatomic outcome (MRI) changes will be evaluated by repeating assessments, clinical tests and imaging exams at the pre-treatment and follow-up visits.

Secondary Outcome Measures :
  1. Speech Therapy Specific Neuropsychological outcome measures [ Time Frame: Two years ]
    Age appropriate Neurologic examinations and speech therapy specific standardized testing will be performed pre-treatment and at all follow-up visits.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Weeks to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Between 6 weeks and 6 years of age on the day of study cord blood infusion.
  2. MRI documented single arterial distribution infarction.
  3. Initial injury occurring in the pre-natal or perinatal period.
  4. Ability of caregivers to understand and speak English
  5. Ability of child and caregiver to travel to Houston, and stay for at least 4 days, and to return for all Follow-up visits (patient is responsible for cost of travel and lodging while in Houston)

Exclusion Criteria:

Inability to obtain all pertinent medical records, including pertinent physician notes, laboratory findings, and radiographic images, related to the original injury, hospitalization and rehabilitation - must be sent to research team at least 14 days prior to scheduled study cord blood treatment.

  1. Recent radiographic evidence (imaging performed within past 2 weeks) of extensive stroke as evidenced by >100ml lesion.
  2. Multifocal infarctions on screening MRI.
  3. Evidence of hypoxic-ischemic encephalopathy on screening MRI.
  4. Uncorrected coagulopathy during the baseline period defined as INR > 1.4; PTT> 35 sec; PLT < 100,000.
  5. Known history of:

    1. Recently diagnosed infection (within past 2 weeks) requiring treatment and/or medical intervention.
    2. Renal disease or altered renal function as defined by serum creatinine > 1.5 mg/dL at admission.
    3. Hepatic disease or altered liver function as defined by SGPT > 150 U/L, and/or T. Bilirubin >1.3 mg/dL at enrollment.
    4. Malignancy.
    5. Immunosuppression as defined by WBC < 3 (10x3) at admission.
    6. HIV, Hepatitis B, Hepatitis C.
  6. Pneumonia, or chronic lung disease requiring oxygen.
  7. Cord blood sample contamination.
  8. Participation in a concurrent intervention study.
  9. Desire for organ-donation in the event of death.
  10. Unwillingness or inability to stay for at least four days following cord blood infusion (should any problems arise following the infusion) and to return for 6 month, 1 year, and 2 year follow-up visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01700166

Layout table for location information
United States, Texas
Children's Memorial Hermann Hospital; University of Texas Health Science Center - Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
James E.Baumgartner, MD
The Institute for Rehabilitaion and Research Foundation
Cord Blood Registry, Inc.
The University of Texas Health Science Center, Houston
M.D. Anderson Cancer Center - Houston
Baylor College of Medicine
Layout table for investigator information
Principal Investigator: Timothy C. Foster, MD The University of Texas Health Science Center, Houston
Principal Investigator: Linda S. Baumgartner, MS, CCC-SLP, LSLS, Cert.AVT Florida Hospital for Children - Orlando
Study Chair: James E. Baumgartner, MD Florida Hospital for Children - Orlando
Layout table for additonal information
Responsible Party: James E.Baumgartner, MD, Clinical Associate Professor; Board-certified Pediatric Neurosurgeon, Memorial Hermann Health System Identifier: NCT01700166    
Other Study ID Numbers: JB IND #14576
First Posted: October 4, 2012    Key Record Dates
Last Update Posted: January 23, 2014
Last Verified: January 2014
Keywords provided by James E.Baumgartner, MD, Memorial Hermann Health System:
Cord Blood
Stem Cells
Pediatric stroke
Children with ischemic stroke
Cerebral Palsy
Perinatal AIS
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases